Decitabine
Hematopoietic Stem Cell Transplantation
Zhejiang UniversitySmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
74 Active assets in the Hematopoietic Stem Cell Transplantation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Busulphan Institute of Hematology & Blood Diseases Hospital, China | Phase 3 | BBB |
Cyclophosphamide The First Affiliated Hospital of Soochow University | Phase 3 | BBB |
FILGRASTIM National Cancer Institute (NCI) | Phase 2/3 | BBB |
Decitabine Chinese PLA General Hospital | Phase 4 | BBB |
Cyclophosphamide St. Jude Children's Research Hospital | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Decitabine is also rated in:
acute myeloid leukemia with t(8;21)(q22;q22) translocationDormant
BB
Indicative ·
70 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →